Corcept Therapeutics Inc Sample Contracts
EXHIBIT 10.6 *CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS LICENSE AGREEMENT Effective as of July 1, 1999 ("Effective...License Agreement • February 10th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
Standard Contracts
EXHIBIT 10.5 INDEMNIFICATION AGREEMENT AGREEMENT, made this ____ day of ___________, 200__, between Corcept Therapeutics Incorporated, a Delaware corporation (the "Company"), and ____________ (the "Indemnitee"). W I T N E S S E T H: - - - - - - - - -...Indemnification Agreement • February 10th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
EXHIBIT 10.9 *CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS Memorandum of Understanding Supply and Services Agreement for...Memorandum of Understanding • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations
Consultant accepts engagement by the Company as a consultant beginning on the Effective Date and continuing until May , 2000, which one-year term will -- be automatically extended for additional one-year periods unless terminated by either party by...Consulting Agreement • February 10th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
INDEMNIFICATION AGREEMENTIndemnification Agreement • November 14th, 2007 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
AGREEMENT, made this day of , 20 , between Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), and (the “Indemnitee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 31st, 2008 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 25, 2008, is by and between CORCEPT THERAPEUTICS INCORPORATED (the “Company”) and KINGSBRIDGE CAPITAL LIMITED (the “Investor”).
EXHIBIT 10.7 Corcept Therapeutics Incorporated PROMISSORY NOTE AND PLEDGE AGREEMENTPromissory Note and Pledge Agreement • December 21st, 2001 • Corcept Therapeutics Inc • California
Corcept Therapeutics Incorporated 10,000,000 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • January 21st, 2011 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (collectively, the “Underwriters”), for whom Stifel, Nicolaus & Company, Incorporated and Leerink Swann LLC are acting as representatives (the “Representatives”), an aggregate of 10,000,000 shares (the “ Firm Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”). The Company also proposes to sell to the several Underwriters, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, up to an additional 1,500,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.
EXHIBIT 4.2 CORCEPT THERAPEUTICS INCORPORATED AMENDED AND RESTATED INFORMATION AND REGISTRATION RIGHTS AGREEMENTInformation and Registration Rights Agreement • February 10th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • March 31st, 2009 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of September 19, 2008 (the “Effective Date”) is entered into by and between Joseph K. Belanoff, MD, Chief Executive Officer (“Executive”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”).
COMMON STOCK PURCHASE AGREEMENT by and between KINGSBRIDGE CAPITAL LIMITED and CORCEPT THERAPEUTICS INCORPORATED dated as of March 25, 2008Common Stock Purchase Agreement • March 31st, 2008 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
This COMMON STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of the 25th day of March, 2008, by and between Kingsbridge Capital Limited, an entity organized and existing under the laws of the British Virgin Islands, whose registered address is Palm Grove House, 2nd Floor, Road Town, Tortola, British Virgin Islands (the “Investor”) and Corcept Therapeutics Incorporated , a corporation organized and existing under the laws of the State of Delaware (the “Company”).
11,000,000 Shares CORCEPT THERAPEUTICS INCORPORATED Common Stock ($0.001 par value) UNDERWRITING AGREEMENTUnderwriting Agreement • July 6th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 29th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 29, 2012, by and among Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), and the investors signatory hereto (each a “Purchaser” and collectively, the “Purchasers”).
AMENDED AND RESTATED EXCLUSIVE WHOLESALE PRODUCT PURCHASE AGREEMENTExclusive Wholesale Product Purchase Agreement • August 9th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED EXCLUSIVE WHOLESALE PRODUCT PURCHASE AGREEMENT (the “Agreement”) is made this 8th day of August, 2012, effective as of the 1st day of March, 2012, (the “Effective Date”) by and between Priority Healthcare Distribution, Inc., doing business as CuraScript SD Specialty Distribution, a Florida corporation having offices at 255 Technology Park, Lake Mary, Florida, 32746 (“Distributor”), and Corcept Therapeutics Incorporated, a Delaware corporation having offices at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Company”). The Parties hereto agree as follows:
COMMERCIAL OUTSOURCING SERVICES AGREEMENTCommercial Outsourcing Services Agreement • August 9th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • Texas
This Commercial Outsourcing Services Agreement (“Agreement”) is entered into as of April 14, 2011 (the “Effective Date”) by INTEGRATED COMMERCIALIZATION SOLUTIONS, INC., a California corporation (“ICS”) and Corcept Therapeutics, INC., a Delaware corporation (the “Company”).
AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • March 31st, 2009 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
THIS AMENDED AND RESTATED SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of September 19, 2008 (the “Effective Date”) is entered into by and between James N. Wilson, Chairman of the Board of Directors (“Executive”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”).
MASTER SERVICES AGREEMENTMaster Services Agreement • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations
This Master Service Agreement (the “Agreement”), made this 17th day of January, 2003 (the “Effective Date”), by and between PPD Development, LP, a Texas limited partnership, with its principal executive offices located at 3151 South 17th Street, Wilmington, North Carolina 28412 (“PPD”) and Corcept with its principal executive offices located at 275 Middlefield Road, Suite A, Menlo Park, California 94025 (“Sponsor”).
MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • May 10th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
[***] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
ContractMaster Services Agreement • August 14th, 2008 • Corcept Therapeutics Inc • Pharmaceutical preparations
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
RESEARCH AGREEMENT/ cGMP MANUFACTURINGResearch Agreement • March 19th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
This agreement is entered into by and between KP Pharmaceutical Technology, Inc., 1212 Rappel Drive, Bloomington 47404 hereinafter called “Research Organization”, and Corcept Therapeutics Incorporated a corporation with its principal office and place of business at 275 Middlefield Road, Suite A, Menlo Park, CA 94025, hereinafter called “Sponsor”.
MASTERMaster Clinical Development Agreement • February 10th, 2004 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • March 1st, 2021 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of March 1, 2021 (the “Effective Date”) is entered into by and between Atabak Mokari, Chief Financial Officer (“CFO”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”).
SEVERANCE AND CHANGE IN CONTROL AGREEMENTSeverance and Change in Control Agreement • May 9th, 2019 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
THIS SEVERANCE AND CHANGE IN CONTROL AGREEMENT (“Agreement”) dated as of March 18, 2019 (the “Effective Date”) is entered into by and between Andreas Grauer, M.D., Chief Medical Officer (“CMO”) and Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”).
September 5, 2012 Manufacturing and Supply AgreementManufacturing and Supply Agreement • May 12th, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
Corcept Therapeutics IncorporatedManufacturing and Supply Agreement • March 14th, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations
On behalf of Corcept Therapeutics Inc. (“Corcept”), I propose amending the Manufacturing and Supply Agreement between Corcept and PCAS dated November 3, 2006 (the “Agreement”) as follows:
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.] SUBLEASE BETWEEN ZUORA,...Sublease • May 1st, 2024 • Corcept Therapeutics Inc • Pharmaceutical preparations • California
WE HEREBY ESTABLISH OUR IRREVOCABLE STANDBY LETTER OF CREDIT NO. SVBSF______ IN YOUR FAVOR AVAILABLE BY PAYMENT AGAINST YOUR PRESENTATION TO US, AT THE BANK’S OFFICE (AS DEFINED BELOW), OF THE FOLLOWING DOCUMENT:
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT NO. 2 TO...Distribution Services Agreement • November 3rd, 2022 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
This Amendment No. 2 to Distribution Services Agreement (this “Amendment”), effective as of September 16, 2022 (the “Amendment Effective Date”), is made by and between Corcept Therapeutics Incorporated, having its principal place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Corcept”) and Optime Care, Inc., having its principal place of business at 4060 Wedgeway Court, Earth City, MO 63045 (“Optime”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Agreement (as defined below).
Manufacturing and Supply AgreementManufacturing Agreement • May 10th, 2012 • Corcept Therapeutics Inc • Pharmaceutical preparations • New York
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.
FIFTH AMENDMENTLease Agreement • August 4th, 2020 • Corcept Therapeutics Inc • Pharmaceutical preparations
THIS FIFTH AMENDMENT (the "Fifth Amendment") is made and entered into as of June 17, 2020 by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation ("Tenant").
Corcept Therapeutics IncorporatedManufacturing and Supply Agreement • March 15th, 2013 • Corcept Therapeutics Inc • Pharmaceutical preparations
On behalf of Corcept Therapeutics Inc. (“Corcept”), I propose amending the Manufacturing and Supply Agreement between Corcept and PCAS dated November 3, 2006 (the “Agreement”) as follows:
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDMENT TO DISTRIBUTION...Distribution Services Agreement • November 3rd, 2022 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
This Amendment to Distribution Services Agreement (this “Amendment”), effective as of August 1, 2022 (the “Amendment Effective Date”), is made by and between Corcept Therapeutics Incorporated, having its principal place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Corcept”) and Optime Care, Inc., having its principal place of business at 4060 Wedgeway Court, Earth City, MO 63045 (“Optime”). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed thereto in the Agreement (as defined below).
COMMERCIAL MANUFACTURING AGREEMENTManufacturing Agreement • August 8th, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS MANUFACTURING AGREEMENT (the “Agreement”) is made and entered into this 7th day of April, 2014 (the “Effective Date”), by and between AAIPharma Services Corp., having a place of business at 2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”) and Corcept Therapeutics Incorporated, having a place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Company”). AAIPharma and Company, as used herein, may be referred to, collectively, as “Parties” and individually as a “Party”.
Corcept Therapeutics IncorporatedRetirement Agreement • August 9th, 2013 • Corcept Therapeutics Inc • Pharmaceutical preparations
This letter describes our agreement regarding your retirement from Corcept, which will take place on December 31, 2013 (the “retirement date”). Until the retirement date, you will continue to serve as our President and Secretary and as a member of Corcept’s Executive Committee at your current salary and benefits, including paid vacation days and access to your current office (together, your “compensation”). Your compensation will remain the same until the retirement date, even if we reduce the scope and scale of your responsibilities or terminate you (unless we terminate you for cause).
NINTH AMENDMENT TO LEASELease • May 1st, 2024 • Corcept Therapeutics Inc • Pharmaceutical preparations
THIS NINTH AMENDMENT TO LEASE (the "Ninth Amendment") is made and entered into as of March 19, 2024, by and between Exponent Realty, LLC, a Delaware limited liability company ("Landlord"), and Corcept Therapeutics Incorporated, a Delaware corporation (“Tenant”).
COMMERCIAL MANUFACTURING AGREEMENTManufacturing Agreement • October 22nd, 2014 • Corcept Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS MANUFACTURING AGREEMENT (the “Agreement”) is made and entered into this 7th day of April, 2014 (the “Effective Date”), by and between AAIPharma Services Corp., having a place of business at 2320 Scientific Park Drive, Wilmington, NC 28405 (“AAIPharma”) and Corcept Therapeutics Incorporated, having a place of business at 149 Commonwealth Drive, Menlo Park, CA 94025 (“Company”). AAIPharma and Company, as used herein, may be referred to, collectively, as “Parties” and individually as a “Party”.
